Imatinib, an ABL kinase inhibitor, is effective for initial treatment of CML, yet a large percentile of CML patients gradually develop resistance [7], due to mutations in BCR-ABL, e.g., T315I, which disrupt imatinib-BCR-ABL interaction [8]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.